The aim of this study was to investigate the pharmacokinetic properties of mosapride after intravenous and oral administration to beagle dogs. To obtain the advanced pharmacokinetic parameters of mosapride, both noncompartmental analysis and pharmacokinetic modeling were performed. Twenty beagle dogs were randomly sorted into intravenous (1 mg single administration of mosapride) and oral (5 mg once a day administration of mosapride) groups. Blood samples were collected according to the reported schedule for pharmacokinetics. The plasma concentration of mosapride was analyzed using liquid chromatography–tandem mass spectrometry. According to the pharmacokinetic analysis, the absorption rate of mosapride was 3.14 ± 1.14 hr⁻¹ and oral bioavailability of mosapride was approximately 1%. The one‐compartment model well described the pharmacokinetics of mosapride after both intravenous and oral administration to dogs. These findings will help facilitate the determination of the optimal dose regimen of mosapride for dogs with gastrointestinal disorder.

中文翻译：

---

在比格犬静脉和口服给药后，莫沙必利的药代动力学分析。

这项研究的目的是调查静脉注射和口服给予比格犬后莫沙必利的药代动力学特性。为了获得莫沙必利的先进药代动力学参数，进行了非房室分析和药代动力学建模。将二十只小猎犬随机分为静脉内（单次给予莫沙必利1 mg）和口服（每天一次给予莫沙必利5 mg）组。根据报道的药代动力学时间表收集血样。使用液相色谱-串联质谱法分析了莫沙必利的血浆浓度。根据药代动力学分析，莫沙必利的吸收率为3.14±1.14 hr ^-1莫沙必利的口服生物利用度约为1％。一室模型很好地描述了莫沙必利对狗静脉和口服给药后的药代动力学。这些发现将有助于为胃肠道疾病的狗确定莫沙必利的最佳剂量方案。